Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4-methyl-n-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide
2. 4-methyl-n-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide Hydrochloride
3. Iy5511
4. Iy5511hcl
1. 926037-48-1
2. Supect
3. Iy-5511
4. Radotinib [inn]
5. Iy5511
6. Radotinib(iy-5511)
7. 4-methyl-n-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyrazin-2-ylpyrimidin-2-yl)amino]benzamide
8. I284ljy110
9. 926037-48-1 (free Base)
10. 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyrazin-2-yl)pyrimidin-2-yl]amino}benzamide
11. 4-methyl-n-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-(pyrazin-2-yl)pyrimidin-2-ylamino)benzamide
12. Iy5511hcl
13. 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(pyrazin-2-yl)pyrimidin-2-yl)amino)benzamide
14. Unii-i284ljy110
15. Radotinib [mi]
16. Radotinib (iy-5511)
17. Radotinib; Iy-5511;
18. Radotinib [who-dd]
19. Gtpl7814
20. Schembl3359952
21. Chembl4297524
22. Dtxsid90239069
23. Bcp12554
24. Ex-a1035
25. Mfcd27956910
26. Nsc800989
27. S8134
28. Zinc59749972
29. Akos026750428
30. Akos032950010
31. Ccg-269914
32. Db12323
33. Iy 5511
34. Nsc-800989
35. Sb11083
36. Ncgc00390586-01
37. Ncgc00481590-01
38. Ac-30633
39. As-55884
40. Da-40474
41. Kb-146009
42. B5846
43. Ft-0700508
44. A13029
45. 2?,3?,17?-trihydroxy-7?-6-oxo-5?-androstan
46. J-690392
47. Q15269680
48. Benzamide, 4-methyl-n-(3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(2-pyrazinyl)-2-pyrimidinyl)amino)-
| Molecular Weight | 530.5 g/mol |
|---|---|
| Molecular Formula | C27H21F3N8O |
| XLogP3 | 3.9 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 6 |
| Exact Mass | 530.17904181 g/mol |
| Monoisotopic Mass | 530.17904181 g/mol |
| Topological Polar Surface Area | 111 Ų |
| Heavy Atom Count | 39 |
| Formal Charge | 0 |
| Complexity | 818 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Radotinib is indicated for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.
Philadelphia chromosome positive (Ph+) leukemia is driven by the constitutive enzymatic activity of the BCR-ABL1 fusion kinase. Tyrosine kinase inhibitors (TKIs) that block the activity of BCR-ABL1 are successfully used clinically to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
ABOUT THIS PAGE
70
PharmaCompass offers a list of Radotinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Radotinib manufacturer or Radotinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Radotinib manufacturer or Radotinib supplier.
PharmaCompass also assists you with knowing the Radotinib API Price utilized in the formulation of products. Radotinib API Price is not always fixed or binding as the Radotinib Price is obtained through a variety of data sources. The Radotinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Radotinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Radotinib, including repackagers and relabelers. The FDA regulates Radotinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Radotinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Radotinib supplier is an individual or a company that provides Radotinib active pharmaceutical ingredient (API) or Radotinib finished formulations upon request. The Radotinib suppliers may include Radotinib API manufacturers, exporters, distributors and traders.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Radotinib Drug Master File in Korea (Radotinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Radotinib. The MFDS reviews the Radotinib KDMF as part of the drug registration process and uses the information provided in the Radotinib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Radotinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Radotinib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Radotinib suppliers with KDMF on PharmaCompass.
Radotinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Radotinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Radotinib GMP manufacturer or Radotinib GMP API supplier for your needs.
A Radotinib CoA (Certificate of Analysis) is a formal document that attests to Radotinib's compliance with Radotinib specifications and serves as a tool for batch-level quality control.
Radotinib CoA mostly includes findings from lab analyses of a specific batch. For each Radotinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Radotinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Radotinib EP), Radotinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Radotinib USP).
